|

Gemcitabine/Cisplatin Clinical Trials

9 actively recruiting trials across 1 location

Also known as: GP, GemCis, Gemzar/Platinol, Induction chemotherapy regimen

Pipeline

Phase 1: 2Phase 2: 2Phase 3: 3Phase 1/2: 2

Top Sponsors

  • Wei Jiang1
  • Tongji Hospital1
  • Tianjin Medical University Cancer Institute and Hospital1
  • Sun Yat-Sen University Cancer Center1
  • Shanghai Jiao Tong University School of Medicine1

Indications

  • Cancer9
  • Nasopharyngeal Carcinoma2
  • Biliary Tract Cancer2
  • Lung Cancer2
  • Recurrent Nasopharynx Carcinoma1

Other8 trials

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
Phase 1
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Phase 1/2
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Phase 1/2
GNT Induction Treatment in Locally Advanced NPC
Phase 3
Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Phase 3
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
Phase 1
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Phase 2
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
Phase 2

Birmingham, Alabama1 trial

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Research Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.